<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TIVICAY- dolutegravir sodiumÂ tablet, film coatedÂ </strong><br>ViiV Healthcare Company<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.<br>TIVICAY (dolutegravir) tablets, for oral use<br>Initial U.S. Approval: 2013</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col width="72%">
<col width="28%">
<tbody class="Headless">
<tr>
<td class="Botrule Toprule"><dl>
<dt>Â </dt>
<dd>Indications and Usage (<a href="#ID_35540a6d-2636-493f-8950-8f9bbe91390a">1</a>)</dd>
</dl></td>
<td class="Botrule Toprule"><dl>
<dt>Â </dt>
<dd>12/2014</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule"><dl>
<dt>Â </dt>
<dd>Dosage and Administration (<a href="#ID_fe0902b6-0d6e-4c30-8e32-33231fd16c6b">2.1</a>, <a href="#ID_667cde5e-9ff6-4f12-96c3-de1657e6f3d2">2.2</a>)</dd>
</dl></td>
<td class="Botrule"><dl>
<dt>Â </dt>
<dd>08/2015</dd>
</dl></td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">TIVICAY is a human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#ID_35540a6d-2636-493f-8950-8f9bbe91390a">1</a>) </p>
<p class="Highlighta">Limitations of Use: </p>
<dl>
<dt>â€¢</dt>
<dd>Use of TIVICAY in integrase strand transfer inhibitor (INSTI)-experienced patients should be guided by the number and type of baseline INSTI substitutions. The efficacy of TIVICAY 50 mg twice daily is reduced in patients with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions including T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R. (<a href="#ID_0a8d29f6-1841-4f83-91ba-cf80028be6e1">12.4</a>)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">May be taken without regard to meals. (<a href="#ID_8f2c467c-aa24-4575-93c2-a09c744e319c">2</a>) </p>
<table width="100%">
<col width="82%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta"><span class="Bold">Adult Population</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta"><span class="Bold">Recommended Dose</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="Highlighta">Treatment-naÃ¯ve or treatment-experienced INSTI-naÃ¯ve (<a href="#ID_fe0902b6-0d6e-4c30-8e32-33231fd16c6b">2.1</a>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">50Â mg once daily </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="Highlighta">Treatment-naÃ¯ve or treatment-experienced INSTI-naÃ¯ve when coadministered with certain UGT1A or CYP3A inducers (<a href="#ID_fe0902b6-0d6e-4c30-8e32-33231fd16c6b">2.1</a>, <a href="#ID_dcd2cd16-34b5-4723-95d3-340da2aef983">7.3</a>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">50Â mg twice daily </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="Highlighta">INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance<span class="Sup">a </span>(<a href="#ID_0a8d29f6-1841-4f83-91ba-cf80028be6e1">12.4</a>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">50Â mg twice daily </p></td>
</tr>
</tbody>
</table>
<p class="Highlighta"><span class="Sup">a</span> Alternative combinations that do not include metabolic inducers should be considered where possible. </p>
<p class="Highlighta"><span class="Bold">Pediatric Patients:</span> (Treatment-naÃ¯ve or treatment-experienced INSTI-naÃ¯ve, aged 12 years and older, and weighing at least 40<span class="Bold">Â </span>kg). (<a href="#ID_667cde5e-9ff6-4f12-96c3-de1657e6f3d2">2.2</a>) </p>
<dl>
<dt>â€¢</dt>
<dd>The recommended dose is TIVICAY 50Â mg once daily.</dd>
<dt>â€¢</dt>
<dd>If certain UGT1A or CYP3A inducers are coadministered, then the recommended dose of TIVICAY is 50Â mg twice daily. (<a href="#ID_667cde5e-9ff6-4f12-96c3-de1657e6f3d2">2.2</a>, <a href="#ID_dcd2cd16-34b5-4723-95d3-340da2aef983">7.3</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>Â </dt>
<dd>Tablets: 50 mg (<a href="#ID_f3828cf2-de25-4065-a22b-96428ae2db4e">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to dolutegravir. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>).</dd>
<dt>â€¢</dt>
<dd>Coadministration with dofetilide. (<a href="#ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> characterized by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, constitutional findings, and sometimes organ dysfunction, including <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, have been reported. Discontinue TIVICAY and other suspect agents immediately if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> develop, as a delay in stopping treatment may result in a life-threatening reaction. (<a href="#ID_27bad223-81e5-4a9c-b653-ec5631b83e77">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY. Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY is recommended in patients with underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C. (<a href="#ID_14f9ed40-f510-4437-8a16-3e528a629326">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>Redistribution/accumulation of body fat and <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span> have been reported in patients treated with combination antiretroviral therapy. (<a href="#ID_251c9e9b-8d9c-402e-933e-51f09083156b">5.3</a>, <a href="#ID_e5744bc5-39b1-4a6b-b5e0-842372f65759">5.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions of moderate to severe intensity and incidence at least 2% (in those receiving TIVICAY in any one adult trial) are <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (<a href="#ID_ca7e5dff-7d49-424c-bd0f-78d63ecf4406">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Drugs that are metabolic inducers may decrease the plasma concentrations of dolutegravir. (<a href="#ID_df686a3b-6218-4ec4-8114-b6c7b639ecf8">7.2</a>, <a href="#ID_dcd2cd16-34b5-4723-95d3-340da2aef983">7.3</a>)</dd>
<dt>â€¢</dt>
<dd>TIVICAY should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral supplements containing iron or calcium, or buffered medications. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food. (<a href="#ID_dcd2cd16-34b5-4723-95d3-340da2aef983">7.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy: TIVICAY should be used during pregnancy only if the potential benefit justifies the potential risk. (<a href="#ID_e50ba56b-d158-4b28-ac99-557d789858a3">8.1</a>)</dd>
<dt>â€¢</dt>
<dd>Nursing mothers: Breastfeeding is not recommended due to the potential for HIV transmission. (<a href="#ID_91fa7bf0-9308-48bc-ae15-cb4b8f9ab630">8.3</a>)</dd>
<dt>â€¢</dt>
<dd>Pediatric patients: Safety and efficacy of TIVICAY have not been established in pediatric patients younger than 12 years or weighing less than 40Â kg, or in pediatric patients who are INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir). (<a href="#ID_605e5dd5-e206-4323-822a-76f89c02e421">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Effects on Serum Liver Biochemistries in Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Fat Redistribution</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience in Adult Subjects</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trials Experience in Pediatric Subjects</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effect of Other Agents on the Pharmacokinetics of Dolutegravir</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Established and Other Potentially Significant Drug Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adult Subjects</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Pediatric Subjects</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_35540a6d-2636-493f-8950-8f9bbe91390a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">TIVICAY<span class="Sup">Â®</span> is indicated in combination with other antiretroviral agents for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Limitations of Use:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="XmChange">Use of TIVICAY in integrase strand transfer inhibitor (INSTI)-experienced patients should be guided by the number and type of baseline INSTI substitutions. The efficacy of TIVICAY 50Â mg twice daily is reduced in patients with an INSTI-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions, including T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R [see Microbiology (12.4)].</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_8f2c467c-aa24-4575-93c2-a09c744e319c"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">TIVICAY tablets may be taken with or without food.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fe0902b6-0d6e-4c30-8e32-33231fd16c6b"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults</h2>
<table width="100%">
<caption><span>Table 1. Dosing Recommendations for TIVICAY in Adult Patients</span></caption>
<col width="77%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Population</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd><span class="Bold">Recommended Dose</span></dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Treatment-naÃ¯ve or treatment-experienced INSTI-naÃ¯ve</p></td>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>50 mg once daily</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First" style="border-left:1px solid;"><span class="XmChange">Treatment-naÃ¯ve or treatment-experienced INSTI-naÃ¯ve when coadministered with certain UGT1A or CYP3A inducers <span class="Italics">[see Drug Interactions (7.3) for relevant inducers]</span></span></p></td>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>50 mg twice daily</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance<span class="Sup">a </span><span class="Italics">[see Microbiology (12.4)]</span></p></td>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>50 mg twice daily</dd>
</dl></td>
</tr>
</tbody>
</table>
<p class="First"><span class="Sup">a </span>Alternative combinations that do not include metabolic inducers should be considered where possible <span class="Italics">[see Drug Interactions (7)]</span>.</p>
<p>The safety and efficacy of doses above 50 mg twice daily have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_667cde5e-9ff6-4f12-96c3-de1657e6f3d2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients</h2>
<p class="First"><span class="Underline">Treatment-naÃ¯ve or Treatment-experienced INSTI-naÃ¯ve</span></p>
<p>The recommended dose of TIVICAY in pediatric patients aged 12 years and older and weighing at least 40Â kg is 50Â mg administered orally once daily.</p>
<p style="border-left:1px solid;"><span class="XmChange">If certain UGT1A or CYP3A inducers are coadministered, then the recommended dose of TIVICAY is 50Â mg twice daily <span class="Italics">[see Drug Interactions (7.3) for relevant inducers]</span>.</span></p>
<p>Safety and efficacy of TIVICAY have not been established in pediatric patients younger than 12 years or weighing less than 40 kg, or in pediatric patients who are INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir).</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_f3828cf2-de25-4065-a22b-96428ae2db4e"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TIVICAY 50-mg tablets are yellow, round, film-coated, biconvex tablets debossed with SVÂ 572 on one side and 50 on the other side. Each tablet contains 50Â mg of dolutegravir (as dolutegravir sodium)<span class="Italics"> [see Description (11)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_f3cd3899-9140-4d06-b3dc-e2fca2bbcb1a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">TIVICAY is contraindicated in patients:</p>
<dl>
<dt>â€¢</dt>
<dd>with previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to dolutegravir <span class="Italics">[see Warnings and Precautions (5.1)].</span>
</dd>
<dt>â€¢</dt>
<dd>receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events<span class="Italics"> [see Drug Interactions (7)]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_70c10965-2048-4a08-ac8a-8f6e912c89e2"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_27bad223-81e5-4a9c-b653-ec5631b83e77"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have been reported and were characterized by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, constitutional findings, and sometimes organ dysfunction, including <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. The events were reported in less than 1% of subjects receiving TIVICAY in Phase 3 clinical trials. Discontinue TIVICAY and other suspect agents immediately if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> develop (including, but not limited to, severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of the skin, oral <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or lesions, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>). Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated. Delay in stopping treatment with TIVICAY or other suspect agents after the onset of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> may result in a life-threatening reaction. TIVICAY is contraindicated in patients who have experienced a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to dolutegravir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_14f9ed40-f510-4437-8a16-3e528a629326"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Effects on Serum Liver Biochemistries in Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></h2>
<p class="First">Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY <span class="Italics">[see Adverse Reactions (6.1)]</span>. In some cases the elevations in transaminases were consistent with <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span> or <span class="product-label-link" type="condition" conceptid="4281232" conceptname="Type B viral hepatitis">hepatitis B reactivation</span> particularly in the setting where anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> therapy was withdrawn. Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_251c9e9b-8d9c-402e-933e-51f09083156b"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat, including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e5744bc5-39b1-4a6b-b5e0-842372f65759"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including TIVICAY. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment. </p>
<p><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_ced153d2-1d08-470b-9c9b-b084c4984fae"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse drug reactions (adverse events assessed as causally related by the investigator or ADRs) are discussed in other sections of the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</dd>
<dt>â€¢</dt>
<dd>Effects on serum liver biochemistries in patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</dd>
<dt>â€¢</dt>
<dd>Fat Redistribution <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</dd>
</dl>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ca7e5dff-7d49-424c-bd0f-78d63ecf4406"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience in Adult Subjects</h2>
<p class="First"><span class="Underline">Treatment</span>â€‘<span class="Underline">emergent Adverse Drug Reactions (ADRs)</span></p>
<p><span class="Italics">Treatment-naÃ¯ve Subjects</span>: The safety assessment of TIVICAY in HIVâ€‘1â€‘infected treatment-naÃ¯ve subjects is based on the analyses of 96-week data from 2 international, multicenter, double-blind trials, SPRING-2 (ING113086) and SINGLE (ING114467) and 48-week data from the international, multicenter, open-label FLAMINGO (ING114915) trial.</p>
<p>In SPRING-2, 822Â subjects were randomized and received at least 1 dose of either TIVICAY 50Â mg once daily or raltegravir 400Â mg twice daily, both in combination with fixed-dose dual nucleoside reverse transcriptase inhibitor (NRTI) treatment (either abacavir sulfate and lamivudine [EPZICOM<span class="Sup">Â®</span>] or emtricitabine/tenofovir [TRUVADA<span class="Sup">Â®</span>]). There were 808 subjects included in the efficacy and safety analyses. Through 96 weeks, the rate of adverse events leading to discontinuation was 2% in both treatment arms.</p>
<p>In SINGLE, 833Â subjects were randomized and received at least 1 dose of either TIVICAY 50Â mg with fixed-dose abacavir sulfate and lamivudine (EPZICOM) once daily or fixed-dose efavirenz/emtricitabine/tenofovir (ATRIPLA<span class="Sup">Â®</span>) once daily. Through 96 weeks, the rates of adverse events leading to discontinuation were 3% in subjects receiving TIVICAY 50Â mg once daily + EPZICOM and 12% in subjects receiving ATRIPLA once daily.</p>
<p>Treatment-emergent ADRs of moderate to severe intensity observed in at least 2% of subjects in either treatment arm in SPRING-2 and SINGLE trials are provided in Table 2. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.</p>
<a name="_RefID0EZAAE"></a><table width="100%">
<caption><span>Table 2. Treatment-emergent Adverse Drug Reactions of at Least Moderate Intensity (Grades 2 to 4) and at Least 2% Frequency in Treatment-naÃ¯ve Subjects in SPRING-2 and SINGLE Trials (Week 96 Analysis)</span></caption>
<col width="23%">
<col width="21%">
<col width="18%">
<col width="23%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">System Organ Class/ Preferred Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">SPRING-2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">SINGLE</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">TIVICAY 50Â mg Once DailyÂ +Â 2 NRTIs </span><br><span class="Bold">(nÂ =Â 403)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Raltegravir</span></p>
<p><span class="Bold">400Â mg Twice DailyÂ +Â 2 NRTIs</span><br><span class="Bold">(nÂ =Â 405)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">TIVICAY 50Â mg +Â EPZICOM Once Daily</span><br><span class="Bold">(nÂ =Â 414)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">ATRIPLA Once Daily</span><br><span class="Bold">(nÂ =Â 419)</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Psychiatric </span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Nervous System</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Gastrointestinal</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">General Disorders</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Ear and Labyrinth</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Includes pooled terms: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, and <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span>.</p>
<p>In addition, Grade 1 <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> was reported by 1% and less than 1% of subjects receiving TIVICAY and raltegravir, respectively, in SPRING-2; whereas in SINGLE the rates were 7% and 4% for TIVICAY and ATRIPLA, respectively. These events were not treatment limiting.</p>
<p>In a multicenter, open-label trial (FLAMINGO), 243 subjects received TIVICAY 50Â mg once daily versus 242 subjects who received darunavir 800Â mg/ritonavir 100Â mg once daily, both in combination with investigator-selected NRTI background regimen (either EPZICOM or TRUVADA). There were 484 subjects included in the efficacy and safety analyses. Through 48 weeks, the rates of adverse events leading to discontinuation were 2% in subjects receiving TIVICAY and 4% in subjects receiving darunavir/ritonavir. The ADRs observed in FLAMINGO were generally consistent with those seen in SPRING-2 and SINGLE.</p>
<p><span class="Italics">Treatment-experienced, Integrase Strand Transfer Inhibitor-naÃ¯ve Subjects</span>: In an international, multicenter, double-blind trial (ING111762, SAILING), 719 HIVâ€‘1â€‘infected, antiretroviral treatment-experienced adults were randomized and received either TIVICAY 50Â mg once daily or raltegravir 400Â mg twice daily with investigator-selected background regimen consisting of up to 2Â agents, including at least one fully active agent. At 48 weeks, the rates of adverse events leading to discontinuation were 3% in subjects receiving TIVICAY 50Â mg once daily + background regimen and 4% in subjects receiving raltegravir 400Â mg twice daily + background regimen.</p>
<p>The only treatment-emergent ADR of moderate to severe intensity with at least 2% frequency in either treatment group was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, 2% (6 of 354) in subjects receiving TIVICAY 50Â mg once dailyÂ +Â background regimen and 1% (5 of 361) in subjects receiving raltegravir 400Â mg twice daily + background regimen.</p>
<p><span class="Italics">Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects</span>: In a multicenter, open-label, single-arm trial (ING112574, VIKING-3), 183Â HIVâ€‘1â€‘infected, antiretroviral treatment-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received TIVICAY 50Â mg twice daily with the current failing background regimen for 7Â days and with optimized background therapy from Day 8. The rate of adverse events leading to discontinuation was 4% of subjects at Week 48. </p>
<p>Treatment-emergent ADRs in VIKING-3 were generally similar compared with observations with the 50-mg once-daily dose in adult Phase 3 trials.</p>
<p><span class="Underline">Less Common Adverse Reactions Observed in Treatment-naÃ¯ve and Treatment-experienced Trials</span></p>
<p>The following ADRs occurred in less than 2% of treatment-naÃ¯ve or treatment-experienced subjects receiving TIVICAY in a combination regimen in any one trial. These events have been included because of their seriousness and assessment of potential causal relationship.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">Myositis</span>.</p>
<p><span class="Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal ideation</span>, attempt, behavior, or completion. These events were observed primarily in subjects with a pre-existing history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other psychiatric illness.</p>
<p><span class="Italics">Renal and Urinary Disorders</span>: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>.</p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>.</p>
<p><span class="Underline">Laboratory Abnormalities</span></p>
<p><span class="Italics">Treatment-naÃ¯ve Subjects</span>: Selected laboratory abnormalities (Grades 2 to 4) with a worsening grade from baseline and representing the worst-grade toxicity in at least 2% of subjects are presented in Table 3. The mean change from baseline observed for selected lipid values is presented in Table 4. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.</p>
<a name="_RefID0E3NAE"></a><table width="100%">
<caption><span>Table 3. Selected Laboratory Abnormalities (Grades 2 to 4) in Treatment-naÃ¯ve Subjects in SPRING-2 and SINGLE Trials (Week 96 Analysis)</span></caption>
<col width="24%">
<col width="20%">
<col width="20%">
<col width="25%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Laboratory Parameter</span></p>
<p><span class="Bold">Preferred Term</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">SPRING-2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">SINGLE</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY 50Â mg Once DailyÂ +</span></p>
<p><span class="Bold">2 NRTIs</span></p>
<p><span class="Bold">(nÂ =Â 403)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Raltegravir</span></p>
<p><span class="Bold">400 mg Twice Daily + 2 NRTIs</span></p>
<p><span class="Bold">(nÂ =Â 405)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY 50Â mg + EPZICOM Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 414)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">ATRIPLA</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 419)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">ALT</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 2 (&gt;2.5-5.0 x ULN)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">4%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 3 to 4 (&gt;5.0 x ULN)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">AST</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 2 (&gt;2.5-5.0 x ULN)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 3 to 4 (&gt;5.0 x ULN)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Total Bilirubin</dd>
</dl></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 2 (1.6-2.5 x ULN)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 3 to 4 (&gt;2.5 x ULN)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Creatine kinase</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 2 (6.0-9.9 x ULN)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">4%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 3 to 4 (â‰¥10.0 x ULN)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 2 (126-250 mg/dL)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">6%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">6%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">7%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 3 (&gt;250 mg/dL)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt;1%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Lipase</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 2 (&gt;1.5-3.0 x ULN)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">7%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">7%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">9%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 3 to 4 (&gt;3.0 x ULN)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Total <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 2 (0.75-0.99 x 109)</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Grade 3 to 4 (&lt;0.75 x 109)</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
</tbody>
</table>
<p>ULN = Upper limit of normal.</p>
<a name="_RefID0EMAAG"></a><table width="100%">
<caption><span>Table 4. Mean Change from Baseline in Fasted Lipid Values in Treatment-naÃ¯ve Subjects in SPRING-2 and SINGLE Trials (Week 96 Analysis<span class="Sup">a</span>)</span></caption>
<col width="17%">
<col width="23%">
<col width="25%">
<col width="24%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Laboratory Parameter</span></p>
<p><span class="Bold">Preferred Term</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">SPRING-2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">SINGLE</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY 50Â mg Once Daily + 2 NRTIs</span></p>
<p><span class="Bold">(nÂ =Â 403)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Raltegravir 400Â mg Twice Daily + 2 NRTIs</span></p>
<p><span class="Bold">(nÂ =Â 405)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY 50Â mg + EPZICOM Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 414)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">ATRIPLA</span></p>
<p><span class="Bold">Once Daily</span></p>
<p><span class="Bold">(nÂ =Â 419)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.1 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10.1 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23.2 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28.0 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.0 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.3 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.2 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.4 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.1 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.1 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14.5 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18.0 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Triglycerides (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.7 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.6 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17.2 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17.4 </p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Subjects on lipid-lowering agents at baseline were excluded from these analyses (19 subjects in each arm in SPRING-2, and in SINGLE: TIVICAY nÂ =Â 30 and ATRIPLA nÂ =Â 27). Seventy-seven subjects initiated a lipid-lowering agent post-baseline; their last fasted on-treatment values (prior to starting the agent) were used regardless if they discontinued the agent (SPRING-2: TIVICAY nÂ =Â 9, raltegravir nÂ =Â 13; SINGLE: TIVICAY nÂ =Â 25 and ATRIPLA: nÂ =Â 30).</p>
<p>Laboratory abnormalities observed in the FLAMINGO trial were generally consistent with observations in SPRING-2 and SINGLE.</p>
<p><span class="Italics">Treatment-experienced, Integrase Strand Transfer Inhibitor-naÃ¯ve Subjects</span>: Laboratory abnormalities observed in SAILING were generally similar compared with observations seen in the treatment-naÃ¯ve (SPRING-2 and SINGLE) trials.</p>
<p><span class="Italics">Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects</span>: The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (10%), creatine kinase (6%), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (14%), and lipase (10%). Two percent (4 of 183) of subjects had a Grade 3 to 4 treatment-emergent hematology laboratory abnormality, with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (2% [3 of 183]) being the most frequently reported.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span>: In Phase 3 trials, subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> were permitted to enroll provided that baseline liver chemistry tests did not exceed 5 times the upper limit of normal. Overall, the safety profile in subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was similar to that observed in subjects without <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, although the rates of AST and ALT abnormalities were higher in the subgroup with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> for all treatment groups. Grades 2 to 4 ALT abnormalities in <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C co-infected compared with HIV mono-infected subjects receiving TIVICAY were observed in 18% vs. 3% with the 50-mg once-daily dose and 13% vs. 8% with the 50-mg twice-daily dose. Liver chemistry elevations consistent with <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span> were observed in some subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C at the start of therapy with TIVICAY, particularly in the setting where anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> therapy was withdrawn <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</p>
<p><span class="Underline">Changes in Serum Creatinine</span></p>
<p>Dolutegravir has been shown to increase serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function <span class="Italics">[see Clinical Pharmacology (12.2)]</span>. Increases in serum creatinine occurred within the first 4 weeks of treatment and remained stable through 48 to 96 weeks. In treatment-naÃ¯ve subjects, a mean change from baseline of 0.15Â mg per dL (range: -0.32Â mg per dL to 0.65Â mg per dL) was observed after 96Â weeks of treatment. Creatinine increases were comparable by background NRTIs and were similar in treatment-experienced subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d27bf0a6-10b6-4311-8cb1-df43afae66e0"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trials Experience in Pediatric Subjects</h2>
<p class="First">IMPAACT P1093 is an ongoing multicenter, open-label, non-comparative trial of approximately 160 HIVâ€‘1â€‘infected pediatric subjects aged 6 weeks to less than 18 years, of which 23 treatment-experienced, INSTI-naÃ¯ve subjects aged 12 to less than 18 years were enrolled <span class="Italics">[see Use in Specific Populations (8.4), Clinical Studies (14.2)].</span></p>
<p>The adverse reaction profile was similar to that for adults. Grade 2 ADRs reported in at least 1 subject were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (nÂ =Â 1), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (nÂ =Â 1), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (nÂ =Â 1). No Grade 3 or 4 ADRs were reported. The Grade 3 laboratory abnormalities were elevated total bilirubin and lipase reported in 1 subject each. No Grade 4 laboratory abnormalities were reported. The changes in mean serum creatinine were similar to those observed in adults. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_98eecaff-c9ce-4839-86ae-193bbefabecd"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d79866f5-8178-411d-8741-b01736eb742d"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents</h2>
<p class="First">In vitro, dolutegravir inhibited the renal organic cation transporters, OCT2 (IC<span class="Sub">50</span> = 1.93 ÂµM) and multidrug and toxin extrusion transporter (MATE) 1 (IC<span class="Sub">50</span> = 6.34 ÂµM). In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1. Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide and metformin, Table 5) <span class="Italics">[see Contraindications (4), Drug Interactions (7.3)]</span>.</p>
<p>In vitro, dolutegravir inhibited the basolateral renal transporters, organic anion transporter (OAT) 1 (IC<span class="Sub">50</span> = 2.12 ÂµM) and OAT3 (IC<span class="Sub">50</span> = 1.97 ÂµM). However, in vivo, dolutegravir did not alter the plasma concentrations of tenofovir or para-amino hippurate, substrates of OAT1 and OAT3.</p>
<p>In vitro, dolutegravir did not inhibit (IC<span class="Sub">50</span> greater than 50 Î¼M) the following: cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1), UGT2B7, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile salt export pump (BSEP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT1, multidrug resistance protein (MRP)2, or MRP4. In vitro, dolutegravir did not induce CYP1A2, CYP2B6, or CYP3A4. Based on these data and the results of drug interaction trials, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters.</p>
<p>In drug interaction trials, dolutegravir did not have a clinically relevant effect on the pharmacokinetics of the following drugs: tenofovir, methadone, midazolam, rilpivirine, and oral contraceptives containing norgestimate and ethinyl estradiol. Using cross-study comparisons to historical pharmacokinetic data for each interacting drug, dolutegravir did not appear to affect the pharmacokinetics of the following drugs: atazanavir, darunavir, efavirenz, etravirine, fosamprenavir, lopinavir, ritonavir, and boceprevir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_df686a3b-6218-4ec4-8114-b6c7b639ecf8"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effect of Other Agents on the Pharmacokinetics of Dolutegravir</h2>
<p class="First">Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A. Dolutegravir is also a substrate of UGT1A3, UGT1A9, BCRP, and P-gp in vitro. Drugs that induce those enzymes and transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir.</p>
<p>Coadministration of dolutegravir and other drugs that inhibit these enzymes may increase dolutegravir plasma concentration.</p>
<p>Etravirine significantly reduced plasma concentrations of dolutegravir, but the effect of etravirine was mitigated by coadministration of lopinavir/ritonavir or darunavir/ritonavir, and is expected to be mitigated by atazanavir/ritonavir (Table 5) <span class="Italics">[see Drug Interactions (7.3), Clinical Pharmacology (12.3)]</span>.</p>
<p>In vitro, dolutegravir was not a substrate of OATP1B1, or OATP1B3.</p>
<p>Darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, tenofovir, boceprevir, prednisone, rifabutin, and omeprazole had no clinically significant effect on the pharmacokinetics of dolutegravir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dcd2cd16-34b5-4723-95d3-340da2aef983"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Established and Other Potentially Significant Drug Interactions</h2>
<p class="First">Table 5 provides clinical recommendations as a result of drug interactions with TIVICAY. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse events or loss of efficacy. <span class="Italics">[See Dosage and Administration (2), Clinical Pharmacology (12.3).]</span></p>
<a name="_RefID0ESJAG"></a><table width="100%">
<caption><span>Table 5. Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Trials or Predicted Interactions [see Dosage and Administration (2)]</span></caption>
<col width="29%">
<col width="20%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Concomitant Drug Class:</span><br><span class="Bold">Drug Name</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Effect on Concentration of Dolutegravir and/or Concomitant Drug</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Clinical Comment</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold"><span class="Italics">HIV-1 Antiviral Agents</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span></p>
<p>Etravirine<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Use of TIVICAY with etravirine without coadministration of atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span></p>
<p>Efavirenz<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule">
<p class="First">Adjust dose of TIVICAY to 50Â mg twice daily for treatment-naÃ¯ve and treatment-experienced, INSTI-naÃ¯ve patients.</p>
<p>Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.<span class="Sup">b</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span></p>
<p>Nevirapine</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Avoid coadministration with nevirapine because there are insufficient data to make dosing recommendations.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Protease Inhibitor:</span></p>
<p>Fosamprenavir/ritonavir<span class="Sup">a</span></p>
<p>Tipranavir/ritonavir<span class="Sup">a</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule">
<p class="First">Adjust dose of TIVICAY to 50Â mg twice daily for treatment-naÃ¯ve and treatment-experienced, INSTI-naÃ¯ve patients. </p>
<p>Use alternative combinations that do not include metabolic inducers where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.<span class="Sup">b</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold"><span class="Italics">Other Agents</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Carbamazepine<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule">
<p class="First">Adjust dose of TIVICAY to 50Â mg twice daily in treatment-naÃ¯ve or treatment-experienced, INSTI-naÃ¯ve patients. </p>
<p>Use alternative treatment that does not include carbamazepine where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.<span class="Sup">b</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Oxcarbazepine<br>Phenytoin<br>Phenobarbital<br>St. Johnâ€™s wort (<span class="Italics">Hypericum perforatum</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Avoid coadministration with TIVICAY because there are insufficient data to make dosing recommendations.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First"><span class="Bold">Medications containing polyvalent cations</span><br><span class="Bold">(e.g., Mg or Al):</span></p>
<p>Cation-containing antacids<span class="Sup">a</span> or laxatives<br>Sucralfate<br>Buffered medications</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Administer TIVICAY 2Â hours before or 6Â hours after taking medications containing polyvalent cations.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Oral calcium or iron supplements, including multivitamins containing calcium or iron</span><span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Administer TIVICAY 2Â hours before or 6Â hours after taking supplements containing calcium or iron. Alternatively, TIVICAY and supplements containing calcium or iron can be taken together with food.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Metformin</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†‘Metformin</p></td>
<td class="Botrule Lrule Rrule"><p class="First">With concomitant use, limit the total daily dose of metformin to 1,000Â mg either when starting metformin or TIVICAY. When stopping TIVICAY, the metformin dose may require an adjustment. Monitoring of blood glucose when initiating concomitant use and after withdrawal of TIVICAY is recommended.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Rifampin<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“Dolutegravir</p></td>
<td class="Botrule Lrule Rrule">
<p class="First">Adjust dose of TIVICAY to 50Â mg twice daily for treatment-naÃ¯ve and treatment-experienced, INSTI-naÃ¯ve patients. </p>
<p>Use alternatives to rifampin where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance.<span class="Sup">b</span></p>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span><span class="Italics">See Clinical Pharmacology (12.3)Table 8 or Table 9 for magnitude of interaction.</span></p>
<p><span class="Sup">b </span>The lower dolutegravir exposures observed in INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance <span class="Italics">[see Microbiology (12.4)]</span>) upon coadministration with certain inducers may result in loss of therapeutic effect and development of resistance to TIVICAY or other coadministered antiretroviral agents. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_e6ce3313-c6a5-42fd-bb1b-6b2f56e05283"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_e50ba56b-d158-4b28-ac99-557d789858a3"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and dolutegravir was shown to cross the placenta in animal studies, this drug should be used during pregnancy only if clearly needed.</p>
<p><span class="Underline">Antiretroviral Pregnancy Registry</span></p>
<p>To monitor maternal-fetal outcomes of pregnant women with HIV exposed to TIVICAY and other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
<p><span class="Underline">Animal Data</span></p>
<p>Reproduction studies have been performed in rats and rabbits at doses up to 27 times the human dose of 50Â mg twice daily and have revealed no evidence of impaired fertility or harm to the fetus due to TIVICAY.</p>
<p>Oral administration of dolutegravir to pregnant rats at doses up to 1,000Â mg per kg daily, approximately 27 times the 50-mg twice-daily human clinical exposure based on AUC, from days 6 to 17 of gestation did not elicit maternal toxicity, developmental toxicity, or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p>Oral administration of dolutegravir to pregnant rabbits at doses up to 1,000Â mg per kg daily, approximately 0.4 times the 50â€‘mg twice-daily human clinical exposure based on AUC, from days 6 to 18 of gestation did not elicit developmental toxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. In rabbits, maternal toxicity (decreased food consumption, scant/no feces/urine, suppressed body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>) was observed at 1,000Â mg per kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_91fa7bf0-9308-48bc-ae15-cb4b8f9ab630"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">The Centers for Disease Control and Prevention recommend that HIVâ€‘1â€‘infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Studies in lactating rats and their offspring indicate that dolutegravir was present in rat milk. It is not known whether dolutegravir is excreted in human milk.</p>
<p>Because of both the potential for HIV transmission and the potential for adverse reactions in nursing infants, <span class="Bold">instruct mothers not to breastfeed.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_605e5dd5-e206-4323-822a-76f89c02e421"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of TIVICAY have not been established in pediatric patients younger than 12Â years, weighing less than 40Â kg, or in any pediatric patients who are INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir).</p>
<p>The safety, virologic, and immunologic responses in subjects who received TIVICAY were evaluated in 23Â treatment-experienced, INSTI-naÃ¯ve, HIVâ€‘1â€“infected subjects aged 12 to less than 18Â years in an open-label, multicenter, dose-finding clinical trial, IMPAACT P1093 <span class="Italics">[see Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.2)]</span>. Pharmacokinetic parameters, evaluated in 9 subjects weighing at least 40Â kg receiving 50Â mg daily and 1 subject (weighing 37Â kg) receiving 35Â mg once daily, were similar to adults receiving 50Â mg once daily. See <span class="Italics">Dosage and Administration (2.2)</span> for dosing recommendations for pediatric patients aged 12 years and older and weighing at least 40Â kg. Frequency, type, and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adults <span class="Italics">[see Adverse Reactions (6.2)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7b58f8fe-28aa-4529-b46f-2d9c7fa87413"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of TIVICAY did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. In general, caution should be exercised in the administration of TIVICAY in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cdd8f215-e128-4a4d-8dee-fdf3dfd65aed"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No clinically important pharmacokinetic differences between subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and matching healthy subjects were observed. No dosage adjustment is necessary for patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score A or B). The effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score C) on the pharmacokinetics of dolutegravir has not been studied. Therefore, TIVICAY is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b01dc070-5222-4604-99f6-3b06156dbca5"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dolutegravir plasma concentrations were decreased in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with those in matched healthy controls. However, no dosage adjustment is necessary for treatment-naÃ¯ve or treatment-experienced and INSTI-naÃ¯ve patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance) with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Caution is warranted for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance <span class="Italics">[see Microbiology (12.4)]</span>) with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, as the decrease in dolutegravir concentrations may result in loss of therapeutic effect and development of resistance to TIVICAY or other coadministered antiretroviral agents <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. Dolutegravir has not been studied in patients on dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_05741435-c3fa-4c5d-967e-8c177be352a7"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no known specific treatment for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with TIVICAY. If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, the patient should be monitored and standard supportive treatment applied as required. As dolutegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_ee09854e-f417-49a1-9ff6-a01dc162be87"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">TIVICAY contains dolutegravir, as dolutegravir sodium, an HIV INSTI. The chemical name of dolutegravir sodium is sodium (4<span class="Italics">R</span>,12a<span class="Italics">S</span>)-9-{[(2,4-difluorophenyl)methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2<span class="Italics">H</span>-pyrido[1',2':4,5]pyrazino[2,1-<span class="Italics">b</span>][1,3]oxazin-7-olate. The empirical formula is C<span class="Sub">20</span>H<span class="Sub">18</span>F<span class="Sub">2</span>N<span class="Sub">3</span>NaO<span class="Sub">5</span> and the molecular weight is 441.36 g per mol. It has the following structural formula:</p>
<div class="Figure">
<a name="id13188873"></a><img alt="dolutegravir chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=63df5af3-b8ac-4e76-9830-2dbb340af922&amp;name=tivicay-spl-graphic-01.jpg">
</div>
<p>Dolutegravir sodium is a white to light yellow powder and is slightly soluble in water.</p>
<p>Each film-coated tablet of TIVICAY for oral administration contains 52.6Â mg of dolutegravir sodium, which is equivalent to 50Â mg dolutegravir free acid, and the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet filmâ€‘coating contains the inactive ingredients iron oxide yellow, macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_cca7b33b-9a57-49ad-ad58-4adb4664d2d1"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_bb92bf86-4de0-4ed9-b692-76b4904563cc"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Dolutegravir is an HIV-1 antiviral agent <span class="Italics">[see Microbiology (12.4)].</span></p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_2a057a5c-33c1-4c56-9f29-b6c2929f8930"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In a randomized, dose-ranging trial, HIVâ€‘1â€‘infected subjects treated with dolutegravir monotherapy demonstrated rapid and dose-dependent antiviral activity with mean declines from baseline to Day 11 in HIV-1 RNA of 1.5, 2.0, and 2.5Â log<span class="Sub">10</span> for dolutegravir 2Â mg, 10Â mg, and 50Â mg once daily, respectively. This antiviral response was maintained for 3 to 4 days after the last dose in the 50-mg group.</p>
<p><span class="Underline">Effects on Electrocardiogram</span></p>
<p>In a randomized, placebo-controlled, cross-over trial, 42Â healthy subjects received single-dose oral administrations of placebo, dolutegravir 250-mg suspension (exposures approximately 3â€“fold of the 50-mg once-daily dose at steady state), and moxifloxacin 400Â mg (active control) in random sequence. After baseline and placebo adjustment, the maximum mean QTc change based on Fridericia correction method (QTcF) for dolutegravir was 2.4Â msec (1-sided 95% upper CI: 4.9Â msec). TIVICAY did not prolong the QTc interval over 24 hours postdose.</p>
<p><span class="Underline">Effects on Renal Function</span></p>
<p>The effect of dolutegravir on renal function was evaluated in an open-label, randomized, 3â€‘arm, parallel, placebo-controlled trial in healthy subjects (nÂ =Â 37) who received dolutegravir 50Â mg once daily (nÂ =Â 12), dolutegravir 50 mg twice daily (nÂ =Â 13), or placebo once daily (nÂ =Â 12) for 14Â days. A decrease in creatinine clearance, as determined by 24-hour urine collection, was observed with both doses of dolutegravir after 14 days of treatment in subjects who received 50Â mg once daily (9% decrease) and 50Â mg twice daily (13% decrease). Neither dose of dolutegravir had a significant effect on the actual glomerular filtration rate (determined by the clearance of probe drug, iohexol) or effective renal plasma flow (determined by the clearance of probe drug, para-amino hippurate) compared with the placebo.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_0cce10ff-903c-47dd-8138-7f5bea219743"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetic properties of dolutegravir have been evaluated in healthy adult subjects and HIVâ€‘1â€“infected adult subjects. Exposure to dolutegravir was generally similar between healthy subjects and HIVâ€‘1â€“infected subjects. The non-linear exposure of dolutegravir following 50Â mg twice daily compared with 50Â mg once daily in HIVâ€‘1â€“infected subjects (TableÂ 6) was attributed to the use of metabolic inducers in the background antiretroviral regimens of subjects receiving dolutegravir 50Â mg twice daily in clinical trials. TIVICAY was administered without regard to food in these trials.</p>
<a name="_RefID0ES1AG"></a><table width="100%">
<caption><span>Table 6. Dolutegravir Steady-state Pharmacokinetic Parameter Estimates in HIVâ€‘1â€“Infected Adults</span></caption>
<col width="29%">
<col width="35%">
<col width="36%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">50Â mg Once Daily</span></p>
<p><span class="Bold">Geometric Mean<span class="Sup">a</span> (%CV)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">50Â mg Twice Daily</span></p>
<p><span class="Bold">Geometric Mean<span class="Sup">b</span> (%CV)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">AUC<span class="Sub">(0-24) </span>(mcg.h/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">53.6 (27)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">75.1 (35)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">C<span class="Sub">max </span>(mcg/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.67 (20)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.15 (29)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">C<span class="Sub">min </span>(mcg/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.11 (46)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.12 (47)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Based on population pharmacokinetic analyses using data from SPRING-1 and SPRING-2.</p>
<p><span class="Sup">b</span>Based on population pharmacokinetic analyses using data from VIKING (ING112961) and VIKING-3.</p>
<p><span class="Underline">Absorption</span></p>
<p>Following oral administration of dolutegravir, peak plasma concentrations were observed 2 to 3 hours postdose. With once-daily dosing, pharmacokinetic steady state is achieved within approximately 5Â days with average accumulation ratios for AUC, C<span class="Sub">max</span>, and C<span class="Sub">24Â h</span> ranging from 1.2 to 1.5. </p>
<p>Dolutegravir plasma concentrations increased in a less than dose-proportional manner above 50Â mg. Dolutegravir is a Pâ€‘gp substrate in vitro. The absolute bioavailability of dolutegravir has not been established.</p>
<p><span class="Underline">Effects of Food on Oral Absorption</span></p>
<p>TIVICAY may be taken with or without food. Food increased the extent of absorption and slowed the rate of absorption of dolutegravir. Low-, moderate-, and high-fat meals increased dolutegravir AUC<span class="Sub">(0-âˆž)</span> by 33%, 41%, and 66%; increased C<span class="Sub">max</span> by 46%, 52%, and 67%; and prolonged T<span class="Sub">max</span> to 3, 4, and 5Â hours from 2Â hours under fasted conditions, respectively.</p>
<p><span class="Underline">Distribution</span></p>
<p>Dolutegravir is highly bound (greater than or equal to 98.9%) to human plasma proteins based on in vivo data and binding is independent of plasma concentration of dolutegravir. The apparent volume of distribution (Vd/F) following 50-mg once-daily administration is estimated at 17.4 L based on a population pharmacokinetic analysis.</p>
<p><span class="Italics">Cerebrospinal Fluid (CSF)</span>: In 12 treatment-naÃ¯ve subjects on dolutegravir 50Â mg daily plus abacavir/lamivudine, the median dolutegravir concentration in CSF was 13.2Â ng per mL (range: 3.74 ng per mL to 18.3 ng per mL) 2 to 6 hours postdose after 16 weeks of treatment. The clinical relevance of this finding has not been established.</p>
<p><span class="Underline">Metabolism and Elimination</span></p>
<p>Dolutegravir is primarily metabolized via UGT1A1 with some contribution from CYP3A. After a single oral dose of [<span class="Sup">14</span>C] dolutegravir, 53% of the total oral dose was excreted unchanged in feces. Thirty-one percent of the total oral dose was excreted in urine, represented by an ether glucuronide of dolutegravir (18.9% of total dose), a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose), and its hydrolytic N-dealkylation product (3.6% of total dose). Renal elimination of unchanged drug was low (less than 1% of the dose). </p>
<p>Dolutegravir has a terminal half-life of approximately 14Â hours and an apparent clearance (CL/F) of 1.0Â L per hour based on population pharmacokinetic analyses.</p>
<p><span class="Italics">Polymorphisms in Drug</span>â€‘<span class="Italics">metabolizing Enzymes</span>: In a meta-analysis of healthy subject trials, subjects with UGT1A1 (nÂ =Â 7) genotypes conferring poor dolutegravir metabolism had a 32% lower clearance of dolutegravir and 46% higher AUC compared with subjects with genotypes associated with normal metabolism via UGT1A1 (nÂ =Â 41).</p>
<p><span class="Underline">Specific Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: Dolutegravir is primarily metabolized and eliminated by the liver. In a trial comparing 8Â subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score B) with 8 matched healthy controls, exposure of dolutegravir from a single 50-mg dose was similar between the 2Â groups. No dosage adjustment is necessary for patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score A or B). The effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Score C) on the pharmacokinetics of dolutegravir has not been studied. Therefore, TIVICAY is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Italics">HBV/HCV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: </span>Population analyses using pooled pharmacokinetic data from adult trials indicated no clinically relevant effect of HCV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> on the pharmacokinetics of dolutegravir. There were limited data on HBV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: Renal clearance of unchanged drug is a minor pathway of elimination for dolutegravir. In a trial comparing 8 subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl less than 30Â mL per min) with 8 matched healthy controls, AUC, C<span class="Sub">max</span>, and C<span class="Sub">24</span> of dolutegravir were decreased by 40%, 23%, and 43%, respectively, compared with those in matched healthy subjects. The cause of this decrease is unknown. Population pharmacokinetic analysis using data from SAILING and VIKING-3 trials indicated that mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had no clinically relevant effect on the exposure of dolutegravir. No dosage adjustment is necessary for treatment-naÃ¯ve or treatment-experienced and INSTI-naÃ¯ve patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance) with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Caution is warranted for INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance <span class="Italics">[see Microbiology (12.4)]</span>) with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, as the decrease in dolutegravir concentrations may result in loss of therapeutic effect and development of resistance to TIVICAY or other coadministered antiretroviral agents. Dolutegravir has not been studied in patients requiring dialysis.</p>
<p><span class="Italics">Gender</span>: Population analyses using pooled pharmacokinetic data from adult trials indicated gender had no clinically relevant effect on the exposure of dolutegravir.</p>
<p><span class="Italics">Race</span>: Population analyses using pooled pharmacokinetic data from adult trials indicated race had no clinically relevant effect on the pharmacokinetics of dolutegravir.</p>
<p><span class="Italics">Geriatric Patients</span>: Population analyses using pooled pharmacokinetic data from adult trials indicated age had no clinically relevant effect on the pharmacokinetics of dolutegravir.</p>
<p><span class="Italics">Pediatric Patients: </span>The pharmacokinetics of dolutegravir in HIVâ€‘1â€“infected children (nÂ =Â 10) aged 12 to less than 18Â years were similar to those observed in HIVâ€‘1â€“infected adults who received dolutegravir 50Â mg once daily (Table 7) <span class="Italics">[see Clinical Studies (14.2)]</span>.</p>
<a name="_RefID0EM1AG"></a><table width="100%">
<caption><span>Table 7. Dolutegravir Steady-state Pharmacokinetic Parameters in Pediatric Subjects</span></caption>
<col width="28%">
<col width="20%">
<col width="17%">
<col width="19%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Age/Weight</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Dose of TIVICAY<span class="Sup">a</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom">
<p class="First"><span class="Bold">Dolutegravir Pharmacokinetic Parameter Estimates</span></p>
<p><span class="Bold">Geometric Mean (%CV)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">C<span class="Sub">max</span></span></p>
<p><span class="Bold">(mcg/mL)</span></p>
<p><span class="Bold">(nÂ =Â 10)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">AUC<span class="Sub">(0-24)</span></span></p>
<p><span class="Bold">(mcg.h/mL)</span></p>
<p><span class="Bold">(nÂ =Â 10)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">C<span class="Sub">24</span></span></p>
<p><span class="Bold">(mcg/mL)</span></p>
<p><span class="Bold">(nÂ =Â 10)</span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">12 to &lt;18Â years and â‰¥40Â kg<span class="Sup"> a</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">50Â mg</p>
<p>once daily</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.49 (38)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46 (43)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.90 (59)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>One subject weighing 37Â kg received TIVICAY 35Â mg once daily. </p>
<p><span class="Underline">Drug Interactions</span></p>
<p>Drug interaction trials were performed with TIVICAY and other drugs likely to be coadministered or commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span>. As dolutegravir is not expected to affect the pharmacokinetics of other drugs dependent on hepatic metabolism (Table 8) <span class="Italics">[see Drug Interactions (7.1)]</span>, the primary focus of these drug interaction trials was to evaluate the effect of coadministered drug on dolutegravir (Table 9).</p>
<p>Dosing or regimen recommendations as a result of established and other potentially significant drug-drug interactions with TIVICAY are provided in Table 5 <span class="Italics">[see Dosage and Administration (2.1), Drug Interactions (7.3)]</span>.</p>
<p><span class="Bold">Table 8. Summary of Effect of Dolutegravir on the Pharmacokinetics of Coadministered Drugs</span></p>
<table width="100%">
<col width="21%">
<col width="14%">
<col width="5%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Coadministered Drug(s)</span></p>
<p><span class="Bold">and Dose(s)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Dose of TIVICAY</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold">Geometric Mean Ratio (90% CI) of Pharmacokinetic Parameters of Coadministered Drug with/without Dolutegravir</span><br><span class="Bold">No EffectÂ =Â 1.00</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">C<span class="Sub">Ï„</span> or C<span class="Sub">24</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ethinyl estradiol<br>0.035Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.99<br>(0.91 to 1.08)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.03<br>(0.96 to 1.11)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.02<br>(0.93 to 1.11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Metformin<br>500Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.66<br>(1.53 to 1.81)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.79<br>(1.65 to 1.93</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">_</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Metformin<br>500Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg<br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.11<br>(1.91 to 2.33)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.45<br>(2.25 to 2.66)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">_</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Methadone<br>16 to 150Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg<br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.00<br>(0.94 to 1.06)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.98<br>(0.91 to 1.06)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.99<br>(0.91 to 1.07)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Midazolam <br>3Â mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">_</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.95<br>(0.79 to 1.15)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">_</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Norelgestromin<br>0.25 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.89<br>(0.82 to 0.97)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.98<br>(0.91 to 1.04)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.93<br>(0.85 to 1.03)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Rilpivirine<br>25Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.10<br>(0.99 to 1.22)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.06<br>(0.98 to 1.16)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.21<br>(1.07 to 1.38)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Tenofovir disoproxil fumarate<br>300Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.09<br>(0.97 to 1.23)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.12<br>(1.01 to 1.24)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.19<br>(1.04 to 1.35)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>The number of subjects represents the maximum number of subjects that were evaluated.</p>
<p><span class="Bold">TableÂ 9. Summary of Effect of Coadministered Drugs on the Pharmacokinetics of Dolutegravir </span></p>
<table width="100%">
<col width="26%">
<col width="14%">
<col width="5%">
<col width="19%">
<col width="19%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">
<p class="First"><span class="Bold">Coadministered Drug(s)</span></p>
<p><span class="Bold">and Dose(s)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Dose of TIVICAY</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold">Geometric Mean Ratio (90% CI) of Dolutegravir Pharmacokinetic Parameters with/without Coadministered Drugs</span><br><span class="Bold">No Effect = 1.00</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">C<span class="Sub">Ï„ </span>or C<span class="Sub">24</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Atazanavir <br>400Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.50<br>(1.40 to 1.59)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.91<br>(1.80 to 2.03)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.80<br>(2.52 to 3.11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Atazanavir/ritonavir<br>300/100Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.34<br>(1.25 to 1.42)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.62<br>(1.50 to 1.74)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.21<br>(1.97 to 2.47)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Darunavir/ritonavir<br>600/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.89<br>(0.83 to 0.97)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.78<br>(0.72 to 0.85)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.62<br>(0.56 to 0.69)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Efavirenz <br>600Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.61<br>(0.51 to 0.73)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.43<br>(0.35 to 0.54)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.25<br>(0.18 to 0.34)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Etravirine<br>200Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.48<br>(0.43 to 0.54)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.29<br>(0.26 to 0.34)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.12<br>(0.09 to 0.16)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Etravirine + darunavir/ritonavir <br>200Â mg + 600/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.88<br>(0.78 to 1.00)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.75<br>(0.69 to 0.81)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.63<br>(0.52 to 0.76)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Etravirine + lopinavir/ritonavir <br>200Â mg + 400/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.07<br>(1.02 to 1.13)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.11<br>(1.02 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.28<br>(1.13 to 1.45)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fosamprenavir/ritonavir<br>700Â mg/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.76<br>(0.63 to 0.92)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.65<br>(0.54 to 0.78)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.51<br>(0.41 to 0.63)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Lopinavir/ritonavir<br>400/100Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.00<br>(0.94 to 1.07)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.97<br>(0.91 to 1.04)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.94<br>(0.85 to 1.05)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Rilpivirine<br>25 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.13 <br>(1.06 to 1.21)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.12 <br>(1.05 to 1.19)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.22 <br>(1.15 to 1.30)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Tenofovir<br>300Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.97<br>(0.87 to 1.08)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.01<br>(0.91 to 1.11)</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.92</p>
<p>(0.82 to 1.04)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Tipranavir/ritonavir<br>500/200Â mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.54<br>(0.50 to 0.57)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.41<br>(0.38 to 0.44)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.24<br>(0.21 to 0.27)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Antacid (Maalox<span class="Sup">Â®</span>)<br>simultaneous administration</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.28<br>(0.23 to 0.33)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.26<br>(0.22 to 0.32)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.26<br>(0.21 to 0.31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Antacid (Maalox<span class="Sup">Â®</span>) <br>2 h after dolutegravir</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.82<br>(0.69 to 0.98)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.74<br>(0.62 to 0.90)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.70<br>(0.58 to 0.85)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Boceprevir<br>800Â mg every 8 hours</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.05<br>(0.96 to 1.15)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.07<br>(0.95 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.08<br>(0.91 to 1.28)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Calcium carbonate 1,200 mg<br>simultaneous administration (fasted)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.63<br>(0.50 to 0.81)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.61<br>(0.47 to 0.80)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.61<br>(0.47 to 0.80)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Calcium carbonate 1,200 mg<br>simultaneous administration (fed)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.07<br>(0.83 to 1.38)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.09<br>(0.84 to 1.43)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.08<br>(0.81 to 1.42)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Calcium carbonate 1,200 mg<br>2 h after dolutegravir</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.00<br>(0.78 to 1.29)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.94<br>(0.72 to 1.23)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.90<br>(0.68 to 1.19)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Carbamazepine<br>300 mg twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16<span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.67<br>(0.61 to 0.73)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.51<br>(0.48 to 0.55)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.27<br>(0.24 to 0.31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ferrous fumarate 324 mg<br>simultaneous administration (fasted)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.43<br>(0.35 to 0.52)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.46<br>(0.38 to 0.56)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.44<br>(0.36 to 0.54)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ferrous fumarate 324 mg<br>simultaneous administration (fed)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.03<br>(0.84 to 1.26)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.98<br>(0.81 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.00<br>(0.81 to 1.23)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Ferrous fumarate 324 mg<br>2 h after dolutegravir</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.99<br>(0.81 to 1.21)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.95<br>(0.77 to 1.15)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.92<br>(0.74 to 1.13)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Multivitamin (One-A-Day<span class="Sup">Â®</span>)<br>simultaneous administration</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.65<br>(0.54 to 0.77)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.67<br>(0.55 to 0.81)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.68<br>(0.56 to 0.82)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Omeprazole<br>40Â mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.92<br>(0.75 to 1.11)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.97<br>(0.78 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.95<br>(0.75 to 1.21)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Prednisone<br>60Â mg once daily with taper</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.06<br>(0.99 to 1.14)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.11<br>(1.03 to 1.20)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.17<br>(1.06 to 1.28)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Rifampin<span class="Sup">a</span><br>600 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.57<br>(0.49 to 0.65)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.46<br>(0.38 to 0.55)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.28<br>(0.23 to 0.34)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Rifampin<span class="Sup">b</span><br>600 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>twice daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.18<br>(1.03 to 1.37)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.33<br>(1.15 to 1.53)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.22<br>(1.01 to 1.48)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Rifabutin<br>300 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50Â mg <br>once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.16<br>(0.98 to 1.37)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.95<br>(0.82 to 1.10)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.70<br>(0.57 to 0.87)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Comparison is rifampin taken with dolutegravir 50Â mg twice daily compared with dolutegravir 50Â mg twice daily.</p>
<p><span class="Sup">b</span>Comparison is rifampin taken with dolutegravir 50Â mg twice daily compared with dolutegravir 50Â mg once daily.</p>
<p><span class="Sup">c</span>The number of subjects represents the maximum number of subjects that were evaluated.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="ID_0a8d29f6-1841-4f83-91ba-cf80028be6e1"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action</span></p>
<p>Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Strand transfer biochemical assays using purified HIV-1 integrase and pre-processed substrate DNA resulted in IC<span class="Sub">50</span> values of 2.7Â nM and 12.6Â nM.</p>
<p><span class="Underline">Antiviral Activity in Cell Culture</span></p>
<p>Dolutegravir exhibited antiviral activity against laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of wild-type HIV-1 with mean EC<span class="Sub">50</span> values of 0.5Â nM (0.21Â ng per mL) to 2.1Â nM (0.85Â ng per mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells. Dolutegravir exhibited antiviral activity against 13 clinically diverse clade B isolates with a mean EC<span class="Sub">50</span> value of 0.52 nM in a viral integrase susceptibility assay using the integrase coding region from clinical isolates. Dolutegravir demonstrated antiviral activity in cell culture against a panel of HIV-1 clinical isolates (3 in each group of M clades A, B, C, D, E, F, and G, and 3 in group O) with EC<span class="Sub">50</span> values ranging from 0.02Â nM to 2.14 nM for HIV-1. Dolutegravir EC<span class="Sub">50</span> values against 3 HIV-2 clinical isolates in PBMC assays ranged from 0.09 nM to 0.61 nM.</p>
<p><span class="Underline">Antiviral Activity in Combination with Other Antiviral Agents</span></p>
<p>The antiviral activity of dolutegravir was not antagonistic when combined with the INSTI, raltegravir; non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz or nevirapine; the nucleoside reverse transcriptase inhibitors (NRTIs), abacavir or stavudine; the protease inhibitors (PIs), amprenavir or lopinavir; the CCR5 co-receptor antagonist, maraviroc; or the fusion inhibitor, enfuvirtide. Dolutegravir antiviral activity was not antagonistic when combined with the HBV reverse transcriptase inhibitor, adefovir, or inhibited by the antiviral, ribavirin.</p>
<p><span class="Underline">Resistance</span></p>
<p><span class="Italics">Cell Culture</span>: Dolutegravir-resistant viruses were selected in cell culture starting from different wild-type HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clades. Amino acid substitutions E92Q, G118R, S153F or Y, G193E or R263K emerged in different passages and conferred decreased susceptibility to dolutegravir of up to 4-fold. Passage of mutant viruses containing the Q148R or Q148H substitutions selected for additional substitutions in integrase that conferred decreased susceptibility to dolutegravir (fold-change increase of 13 to 46). The additional integrase substitutions included T97A, E138K, G140S, and M154I. Passage of mutant viruses containing both G140S and Q148H selected for L74M, E92Q, and N155H.</p>
<p><span class="Italics">Treatment-naÃ¯ve Subjects</span>: No subjects in the dolutegravir 50-mg once-daily treatment arms of treatment-naÃ¯ve trials SPRING-2 and SINGLE had a detectable decrease in susceptibility to dolutegravir or background NRTIs in the resistance analysis subset (nÂ =Â 9) with HIV-1 RNA greater than 400 copies per mL at failure or last visit through Week 96 and having resistance data. One subject in SINGLE with 275 copies per mL HIV-1 RNA had a treatment-emergent integrase substitution (E157Q/P) detected at Week 24, but no corresponding decrease in dolutegravir susceptibility. No treatment-emergent genotypic resistance to the background regimen was observed in the dolutegravir arm in either the SPRING-2 or SINGLE trials. No treatment-emergent primary resistance substitutions were observed in either treatment group in the FLAMINGO trial.</p>
<p><span class="Italics">Treatment-experienced, Integrase Strand Transfer Inhibitor-naÃ¯ve Subjects</span>: In the dolutegravir arm of the SAILING trial for treatment-experienced and INSTI-naÃ¯ve subjects (nÂ =Â 354), treatment-emergent integrase substitutions were observed in 6 of 28 (21%) subjects who had virologic failure and resistance data. In 5 of the 6 subjectsâ€™ isolates emergent INSTI substitutions included L74L/M/I, Q95Q/L, V151V/I (nÂ =Â 1 each), and R263K (nÂ =Â 2). The change in dolutegravir phenotypic susceptibility for these 5 subject isolates was less than 2-fold. One subject isolate had pre-existing raltegravir resistance substitutions E138A, G140S, and Q148H at baseline and had additional emergent INSTI-resistance substitutions T97A and E138A/T with a corresponding 148-fold reduction in dolutegravir susceptibility at failure. In the comparator raltegravir arm, 21 of 49 (43%) subjects with post-baseline resistance data had evidence of emergent INSTI-resistance substitutions (L74M, E92Q, T97A, E138Q, G140S/A, Y143R/C, Q148H/R, V151I, N155H, E157Q, and G163K/R) and raltegravir phenotypic resistance.</p>
<p><span class="Italics">Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects</span>: VIKING-3 examined the efficacy of dolutegravir 50 mg twice daily plus optimized background therapy in subjects with prior or current virologic failure on an INSTI- (elvitegravir or raltegravir) containing regimen.</p>
<p>In VIKING-4 (ING116529),30 subjects with current virological failure on an INSTI-containing regimen and genotypic evidence of INSTI-resistance substitutions at screening were randomized to receive either dolutegravir 50Â mg twice daily or placebo with the current failing regimen for 7 days and then all subjects received open-label dolutegravir plus optimized background regimen from Day 8. Virologic responses at Week 48 by baseline genotypic and phenotypic INSTI-resistance categories and the INSTI resistance-associated substitutions that emerged on dolutegravir treatment in VIKING-4 were consistent with those seen in VIKING-3.</p>
<p><span class="Underline">Response by Baseline Genotype</span></p>
<p>Of the 183 subjects with baseline data, 30% harbored virus with a substitution at Q148, and 33% had no primary INSTI-resistance substitutions (T66A/I/K, E92Q/V, Y143R/C/H, Q148H/R/K, and N155H) at baseline, but had historical genotypic evidence of INSTI-resistance substitutions, phenotypic evidence of elvitegravir or raltegravir resistance, or genotypic evidence of INSTI-resistance substitutions at screening.</p>
<p>Response rates by baseline genotype were analyzed in an â€œas-treatedâ€? analysis at Week 48 (nÂ =Â 175) (Table 10). The response rate at Week 48 to dolutegravir-containing regimens was 47% (24 of 51) when Q148 substitutions were present at baseline; Q148 was always present with additional INSTI-resistance substitutions (see Table 10). In addition, a diminished virologic response of 40% (6 of 15) was observed when the substitution E157Q or K was present at baseline with other INSTI-resistance substitutions but without a Q148H or R substitution.</p>
<p><span class="Bold">Table 10. Response by Baseline Integrase Genotype in Subjects with Prior Experience to an Integrase Strand Transfer Inhibitor in VIKING-3</span></p>
<table width="100%">
<col width="80%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Baseline Genotype</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Week 48</span><br><span class="Bold">(&lt;50 copies/mL)</span><br><span class="Bold">nÂ =Â 175</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Overall Response</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">66% (116/175)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">No Q148 substitution<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">74% (92/124)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Q148H/R + G140S/A/C without additional INSTI-resistance substitution<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">61% (17/28)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Q148H/R + â‰¥2 INSTI-resistance substitutions<span class="Sup">b,c</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">29% (6/21)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Includes INSTI-resistance substitutions Y143R/C/H and N155H.</p>
<p><span class="Sup">b</span>INSTI-resistance substitutions included T66A, L74I/M, E138A/K/T, G140S/A/C, Y143R/C/H, E157Q, G163S/E/K/Q, or G193E/R. Two additional subjects had baseline genotypes of Q148Q/R plus L74L/I/M (virologic failure) and Q148R plus E138K (responder).</p>
<p><span class="Sup">c</span>The most common pathway with Q148H/R + greater than or equal to 2 INSTI-resistance substitutions had Q148+G140+E138 substitutions (nÂ =Â 16).</p>
<p><span class="Underline">Response by Baseline Phenotype</span></p>
<p>Response rates by baseline phenotype were analyzed in an as-treated analysis using all subjects with available baseline phenotypes through Week 48 (nÂ =Â 163) (see Table 11). These baseline phenotypic groups are based on subjects enrolled in VIKING-3 and are not meant to represent definitive clinical susceptibility cut points for dolutegravir. The data are provided to guide clinicians on the likelihood of virologic success based on pretreatment susceptibility to dolutegravir in INSTI-resistant patients.</p>
<p><span class="Bold">Table 11. Response by Baseline Dolutegravir Phenotype (Fold-change from Reference) in Subjects with Prior Experience to an Integrase Strand Transfer Inhibitor in VIKING-3</span></p>
<table width="100%">
<col width="58%">
<col width="42%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><dl>
<dt>Â </dt>
<dd>
<span class="Bold">Baseline Dolutegravir Phenotype</span><br><span class="Bold">(Fold-change from Reference)</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><dl>
<dt>Â </dt>
<dd>
<span class="Bold">Response at Week 48</span><br><span class="Bold">(&lt;50 copies/mL)</span><br><span class="Bold">Subset nÂ =Â 163</span>
</dd>
</dl></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Overall Response</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">64% (104/163)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">&lt;3-fold change</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">72% (83/116)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">3- &lt;10-fold change</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">53% (18/34)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">â‰¥10-fold change</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">23% (3/13)</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Integrase Strand Transfer Inhibitor Treatment-emergent Resistance</span></p>
<p>There were 50 subjects with virologic failure on the dolutegravir twice-daily regimen in VIKING-3 with HIV-1 RNA greater than 400 copies per mL at the failure timepoint, Week 48 or beyond, or the last timepoint on trial. Thirty-nine subjects with virologic failure had resistance data that were used in the Week 48 analysis. In the Week 48 resistance analysis 85% (33 of 39) of the subjects with virologic failure had treatment-emergent INSTI-resistance substitutions in their isolates. The most common treatment-emergent INSTI-resistance substitution was T97A. Other frequently emergent INSTI-resistance substitutions included L74M, I or V, E138K or A, G140S, Q148H, R or K, M154I, or N155H. Substitutions E92Q, Y143R or C/H, S147G, V151A, and E157E/Q each emerged in 1 to 3 subjectsâ€™ isolates. At failure, the median dolutegravir fold-change from reference was 61-fold (range: 0.75 to 209) for isolates with emergent INSTI-resistance substitutions (nÂ =Â 33). </p>
<p>Resistance to one or more background drugs in the dolutegravir twice-daily regimen also emerged in 49% (19 of 39) subjects in the Week 48 resistance analysis<span class="Bold">.</span></p>
<p><span class="Underline">Cross-resistance</span></p>
<p><span class="Italics">Site-directed Integrase Strand Transfer Inhibitor-resistant Mutant HIV-1 and HIV-2 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span></span>: The susceptibility of dolutegravir was tested against 60 INSTI-resistant site-directed mutant HIV-1 viruses (28 with single substitutions and 32 with 2 or more substitutions) and 6 INSTI-resistant site-directed mutant HIV-2 viruses. The single INSTI-resistance substitutions T66K, I151L, and S153Y conferred a greater than 2-fold decrease in dolutegravir susceptibility (range: 2.3-fold to 3.6-fold from reference). Combinations of multiple substitutions T66K/L74M, E92Q/N155H, G140C/Q148R, G140S/Q148H, R or K, Q148R/N155H, T97A/G140S/Q148, and substitutions at E138/G140/Q148 showed a greater than 2-fold decrease in dolutegravir susceptibility (range: 2.5-fold to 21-fold from reference). In HIV-2 mutants, combinations of substitutions A153G/N155H/S163G and E92Q/T97A/N155H/S163D conferred 4-fold decreases in dolutegravir susceptibility, and E92Q/N155H and G140S/Q148R showed 8.5-fold and 17-fold decreases in dolutegravir susceptibility, respectively.</p>
<p><span class="Italics">Reverse Transcriptase Inhibitor- and Protease Inhibitor-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span></span>: Dolutegravir demonstrated equivalent antiviral activity against 2 NNRTI-resistant, 3 NRTI-resistant, and 2 PI-resistant HIV-1 mutant clones compared with the wild-type <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_0659d06b-bb62-4d06-932a-c897374208f9"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_8ea35738-bbb2-4959-ae6e-2ea3f1396d60"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Two-year carcinogenicity studies in mice and rats were conducted with dolutegravir. Mice were administered doses of up to 500Â mg per kg, and rats were administered doses of up to 50Â mg per kg. In mice, no significant increases in the incidence of drug-related neoplasms were observed at the highest doses tested, resulting in dolutegravir AUC exposures approximately 14-fold higher than those in humans at the recommended dose of 50Â mg twice daily. In rats, no increases in the incidence of drug-related neoplasms were observed at the highest dose tested, resulting in dolutegravir AUC exposures 10-fold and 15-fold higher in males and females, respectively, than those in humans at the recommended dose of 50Â mg twice daily.</p>
<p><span class="Underline">Mutagenesis</span></p>
<p>Dolutegravir was not genotoxic in the bacterial reverse mutation assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, or in the in vivo rodent micronucleus assay.</p>
<p><span class="Underline">Impairment of Fertility</span></p>
<p>In a study conducted in rats, there were no effects on mating or fertility with dolutegravir up to 1,000 mg per kg per day. This dose is associated with an exposure that is approximately 24 times higher than the exposure in humans at the recommended dose of 50Â mg twice daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_8895ad2d-fbf4-4f7c-9676-c496aaf50618"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of TIVICAY is based on analyses of data from 3 trials, SPRING-2 (ING113086), SINGLE (ING114467), and FLAMINGO (ING114915), in treatment-naÃ¯ve, HIVâ€‘1â€‘infected subjects (nÂ =Â 2,125); one trial, SAILING (ING111762), in treatment-experienced, INSTI-naÃ¯ve HIVâ€‘1â€‘infected subjects (nÂ =Â 715); and from VIKING-3 (ING112574) trial in INSTI-experienced HIVâ€‘1â€‘infected subjects (nÂ =Â 183). The use of TIVICAY in pediatric patients aged 12 years and older is based on evaluation of safety, pharmacokinetics, and efficacy through 24 weeks in a multicenter, open-label trial in subjects (nÂ =Â 23) without INSTI resistance.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_31b2aa54-1d1e-4b30-b430-6d48d81e29e1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adult Subjects</h2>
<p class="First"><span class="Underline">Treatment-naÃ¯ve Subjects</span></p>
<p>In SPRING-2, 822Â subjects were randomized and received at least 1 dose of either TIVICAY 50Â mg once daily or raltegravir 400Â mg twice daily, both in combination with fixed-dose dual NRTI treatment (either abacavir sulfate and lamivudine [EPZICOM] or emtricitabine/tenofovir [TRUVADA]). There were 808 subjects included in the efficacy and safety analyses. At baseline, the median age of subjects was 36 years, 13% female, 15% non-white, 11% had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 2% were CDC Class C (AIDS), 28% had HIV-1 RNA greater than 100,000 copies per mL, 48% had CD4+ cell count less than 350 cells per mm<span class="Sup">3</span>, and 39% received EPZICOM; these characteristics were similar between treatment groups.</p>
<p>In SINGLE, 833Â subjects were randomized and received at least 1 dose of either TIVICAY 50Â mg once daily with fixed-dose abacavir sulfate and lamivudine (EPZICOM) or fixed-dose efavirenz/emtricitabine/tenofovir (ATRIPLA). At baseline, the median age of subjects was 35 years, 16% female, 32% non-white, 7% had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was excluded), 4% were CDC Class C (AIDS), 32% had HIV-1 RNA greater than 100,000 copies per mL, and 53% had CD4+ cell count less than 350 cells per mm<span class="Sup">3</span>; these characteristics were similar between treatment groups.</p>
<p>Week 96 outcomes for SPRING-2 and SINGLE are provided in Table 12. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.</p>
<p><span class="Bold">Table 12. Virologic Outcomes of Randomized Treatment in SPRING-2 and SINGLE at Week 96 (Snapshot Algorithm)</span></p>
<table width="100%">
<col width="35%">
<col width="16%">
<col width="17%">
<col width="17%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">SPRING-2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">SINGLE</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">TIVICAY</span><br><span class="Bold">50Â mg Once Daily + 2 NRTIs</span><br><span class="Bold">(nÂ =Â 403)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Raltegravir</span><br><span class="Bold">400Â mg Twice Daily + 2 NRTIs</span><br><span class="Bold">(nÂ =Â 405)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">TIVICAY</span><br><span class="Bold">50Â mg + EPZICOM Once Daily</span><br><span class="Bold">(nÂ =Â 414)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">ATRIPLA Once Daily</span><br><span class="Bold">(nÂ =Â 419)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HIV-1 RNA &lt;50 copies/mL </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">82%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">78%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">72%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Treatment differencea</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">4.9% (95% CI: -0.6%, 10.3%)</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">8.0% (95% CI: 2.3%, 13.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Virologic nonresponse</span><span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">No virologic data </span></p></td>
<td align="center"><p class="First">12%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">12%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">12%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">20%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Reasons</p></td>
<td></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Discontinued study/study drug due to adverse event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">c </span>
</dd>
</dl></td>
<td align="center"><p class="First">2%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">11%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Discontinued study/study drug for other reasons<span class="Sup">d</span>
</dd>
</dl></td>
<td align="center"><p class="First">8%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">9%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">9%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Missing data during window but on study</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">&lt;</span>1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">&lt;</span>1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="5"><p class="First"><span class="Bold">Proportion (%) of Subjects with HIV-1 RNA &lt;50Â copies/mL by Baseline Category</span></p></td></tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Plasma viral load (copies/mL)</span></p></td>
<td></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>â‰¤100,000 </dd>
</dl></td>
<td align="center"><p class="First">84%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">83%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">85%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">73%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>&gt;100,000<span class="Sup">e</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">79%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">63%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">71%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">72%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Gender</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Male </dd>
</dl></td>
<td align="center"><p class="First">84%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">79%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">81%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">75%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Female </dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">70%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">68%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">76%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">56%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Race </span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>White </dd>
</dl></td>
<td align="center"><p class="First">83%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">78%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">79%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">77%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>African-American/African Heritage/Other</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">77%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">75%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">83%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Adjusted for pre-specified stratification factors.</p>
<p><span class="Sup">b</span>Includes subjects who changed background regimen (BR) to new class or changed BR not permitted per protocol or due to lack of efficacy prior to Week 96 (for SPRING-2 only), subjects who discontinued prior to Week 96 for lack or loss of efficacy, and subjects who were HIV-1 RNA greater than or equal to 50Â copies per mL in the Week 48 window. </p>
<p><span class="Sup">c</span>Includes subjects who discontinued due to an adverse event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at any time point from Day 1 through the Week 96 window if this resulted in no virologic data on treatment during the Week 96 window. </p>
<p><span class="Sup">d</span>Other includes reasons such as withdrew consent, loss to follow-up, moved, and protocol deviation.</p>
<p><span class="Sup">e</span> In SINGLE, the proportion of subjects who had no virologic data due to reasons such as withdrew consent, lost to follow-up, moved, and protocol deviation was 10% (TIVICAYÂ +Â EPZICOM) and 6% (ATRIPLA) in the greater-than-100,000â€“copies-per-mL group and 8% and 9% (respectively) in the less-than-or-equal-to-100,000â€“copies-per-mL group.</p>
<p><span class="Italics">SPRING-2</span>: Virologic outcomes were also comparable across baseline characteristics including CD4+ cell count, age, and use of EPZICOM or TRUVADA as NRTI background regimen. The median change in CD4+ cell counts from baseline were 276Â cells per mm<span class="Sup">3</span> in the group receiving TIVICAY and 264Â cells per mm<span class="Sup">3</span> for the raltegravir group at 96Â weeks.</p>
<p>There was no treatment-emergent resistance to dolutegravir or to the NRTI background.</p>
<p><span class="Italics">SINGLE</span>: Treatment differences were maintained across baseline characteristics including CD4+ cell count, age, gender, and race.</p>
<p>The adjusted mean changes in CD4+ cell counts from baseline were 325 cells per mm<span class="Sup">3</span> in the group receiving TIVICAY + EPZICOM and 281 cells per mm<span class="Sup">3</span> for the ATRIPLA group at 96 weeks. The adjusted difference between treatment arms and 95% CI was 44.0 cells per mm<span class="Sup">3</span> (14.3 cells per mm<span class="Sup">3</span>, 73.6 cells per mm<span class="Sup">3</span>) (adjusted for pre-specified stratification factors: baseline HIV-1 RNA, baseline CD4+ cell count, and multiplicity).</p>
<p>There was no treatment-emergent resistance to dolutegravir, abacavir, or lamivudine.</p>
<p><span class="Italics">FLAMINGO:</span> In FLAMINGO, 485 subjects were randomized and received at least 1 dose of either TIVICAY 50Â mg once daily (nÂ =Â 243) or darunavirÂ +Â ritonavir 800 mg/100Â mg once daily (nÂ =Â 242), both in combination with investigator-selected NRTI background regimen (either fixed-dose abacavir and lamivudine [EPZICOM] or fixed-dose emtricitabine/tenofovir disoproxil fumarate [TRUVADA]). There were 484 subjects included in the efficacy and safety analyses. At baseline, the median age of subjects was 34 years, 15% female, 28% non-white, 10% had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 3% were CDC Class C (AIDS), 25% had HIVâ€‘1 RNA greater than 100,000 copies per mL, and 35% had CD4+ cell count less than 350Â cells per mm<span class="Sup">3</span>; these characteristics were similar between treatment groups. Overall response rates by Snapshot algorithm through Week 48 were 90% for TIVICAY and 83% for darunavir/ritonavir. The adjusted difference in proportion and 95% CI was 7.1% (0.9%, 13.2%). No treatment-emergent primary resistance substitutions were observed in either treatment group.</p>
<p><span class="Underline">Treatment-experienced, Integrase Strand Transfer Inhibitor-naÃ¯ve Subjects</span></p>
<p>In the international, multicenter, double-blind trial (SAILING), 719Â HIVâ€‘1â€‘ infected, antiretroviral treatment-experienced adults were randomized and received either TIVICAY 50Â mg once daily or raltegravir 400Â mg twice daily with investigator-selected background regimen consisting of up to 2Â agents, including at least 1 fully active agent. There were 715 subjects included in the efficacy and safety analyses. At baseline, the median age was 43 years, 32% were female, 50% non-white, 16% had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 46% were CDC Class C (AIDS), 20% had HIV-1 RNA greater than 100,000 copies per mL, and 72% had CD4+ cell count less than 350 cells per mm<span class="Sup">3</span>; these characteristics were similar between treatment groups. All subjects had at least 2-class antiretroviral treatment resistance, and 49% of subjects had at least 3-class antiretroviral treatment resistance at baseline. Week 48 outcomes for SAILING are shown in TableÂ 13.</p>
<p><span class="Bold">Table 13. Virologic Outcomes of Randomized Treatment in SAILING at 48 Weeks (Snapshot Algorithm)</span></p>
<table width="100%">
<col width="62%">
<col width="18%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY 50Â mg </span><br><span class="Bold">Once Daily + BR<span class="Sup">a</span></span></p>
<p><span class="Bold">(nÂ =Â 354)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Raltegravir 400Â mg </span><br><span class="Bold">Twice Daily + BR<span class="Sup">a</span></span></p>
<p><span class="Bold">(nÂ =Â 361)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HIV-1 RNA &lt;50Â copies/mL </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">71%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Adjusted<span class="Sup">b</span> treatment difference </dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First">7.4% (95% CI: 0.7%, 14.2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Virologic nonresponse</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">No virologic data </span></p></td>
<td class="Lrule Rrule" align="center"><p class="First">9%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Reasons</p></td>
<td></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Discontinued study/study drug due to adverse event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></dd>
</dl></td>
<td align="center"><p class="First">3%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Discontinued study/study drug for other reasons<span class="Sup">c</span>
</dd>
</dl></td>
<td align="center"><p class="First">5%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Missing data during window but on study</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First"><span class="Bold">Proportion (%) with HIV-1 RNA &lt;50Â copies/mL by Baseline Category</span></p></td></tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Plasma viral load (copies/mL)</span></p></td>
<td></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>â‰¤50,000 copies/mL</dd>
</dl></td>
<td align="center"><p class="First">75%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">71%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>&gt;50,000 copies/mL</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">62%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">47%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Background regimen</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>No darunavir use </dd>
</dl></td>
<td align="center"><p class="First">67%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">60%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Darunavir use with primary PI substitutions</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">85%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">67%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Darunavir use without primary PI substitutions</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">69%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">70%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Gender</span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Male </dd>
</dl></td>
<td align="center"><p class="First">70%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">66%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Female </dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">74%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">60%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Race </span></p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>White </dd>
</dl></td>
<td align="center"><p class="First">75%</p></td>
<td class="Lrule Rrule" align="center"><p class="First">71%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>African-American/African Heritage/Other</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">67%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">57%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>BR = Background regimen. Background regimen was restricted to less than or equal to 2 antiretroviral treatments with at least 1 fully active agent.</p>
<p><span class="Sup">b</span>Adjusted for pre-specified stratification factors. </p>
<p><span class="Sup">c</span>Other includes reasons such as withdrew consent, loss to follow-up, moved, and protocol deviation.</p>
<p>Treatment differences were maintained across the baseline characteristics including CD4+ cell count and age.</p>
<p>The mean changes in CD4+ cell counts from baseline were 162Â cells per mm<span class="Sup">3</span> in the group receiving TIVICAY and 153Â cells per mm<span class="Sup">3</span> in the raltegravir group.</p>
<p><span class="Underline">Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects</span></p>
<p>VIKING-3 examined the effect of TIVICAY 50Â mg twice daily over 7 days of functional monotherapy, followed by optimized background therapy (OBT) with continued treatment of TIVICAY 50Â mg twice daily.</p>
<p>In the multicenter, open-label, single-arm VIKING-3 trial, 183Â HIVâ€‘1â€‘infected, antiretroviral treatment-experienced adults with virological failure and current or historical evidence of raltegravir and/or elvitegravir resistance received TIVICAY 50Â mg twice daily with the current failing background regimen for 7Â days, then received TIVICAY with OBT from Day 8. A total of 183Â subjects enrolled: 133Â subjects with INSTI resistance at screening and 50Â subjects with only historical evidence of resistance (and not at screening). At baseline, median age of subjects was 48Â years; 23% were female, 29% non-white, and 20% had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Median baseline CD4+ cell count was 140Â cells per mm<span class="Sup">3</span>, median duration of prior antiretroviral treatment was 13Â years, and 56% were CDC Class C. Subjects showed multiple-class antiretroviral treatment resistance at baseline: 79% had greater than or equal to 2 NRTI, 75% greater than or equal to 1 NNRTI, and 71% greater than or equal to 2 PI major substitutions; 62% had non-R5 virus. </p>
<p>Mean reduction from baseline in HIV-1 RNA at Day 8 (primary endpoint) was 1.4 log<span class="Sub">10 </span>(95% CI: 1.3 log<span class="Sub">10</span>, 1.5 log<span class="Sub">10</span>). Response at Week 48 was affected by baseline INSTI substitutions <span class="Italics">[see Microbiology (12.4)]</span>.</p>
<p>After the functional monotherapy phase, subjects had the opportunity to re-optimize their background regimen when possible. Week 48 virologic outcomes for VIKING-3 are shown in Table 14.</p>
<p><span class="Bold">Table 14. Virologic Outcomes of Treatment of VIKING-3 at 48 Weeks (Snapshot Algorithm)</span></p>
<table width="100%">
<col width="63%">
<col width="37%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">TIVICAY 50Â mg Twice Daily + OBT</span></p>
<p><span class="Bold">(nÂ =Â 183)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">HIV-1 RNA &lt;50Â copies/mL</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">63%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Virologic nonresponse</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32%</p></td>
</tr>
<tr>
<td class="Lrule Rrule">
<p class="First"><span class="Bold">No virologic data</span></p>
<p>Reasons</p>
</td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Discontinued study/study drug due to adverse event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Proportion (%) with HIV-1 RNA &lt;50Â copies/mL by Baseline Category</span></p></td></tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Gender</span></p></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Male </dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">63%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Female </dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64%</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Race </span></p></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>White </dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">63%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>African-American/African Heritage/Other</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64%</p></td>
</tr>
</tbody>
</table>
<p>Subjects harboring virus with Q148 and with additional Q148-associated secondary substitutions also had a reduced response at Week 48 in a stepwise fashion <span class="Italics">[see Microbiology (12.4)].</span></p>
<p>The median change in CD4+ cell count from baseline was 80Â cells per mm<span class="Sup">3</span> at Week 48.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c44b00d8-c40e-4e25-84a2-f3df9999eea0"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Pediatric Subjects</h2>
<p class="First">IMPAACT P1093 is a Phase 1/2, 48-week, multicenter, open-label trial to evaluate the pharmacokinetic parameters, safety, tolerability, and efficacy of TIVICAY in combination treatment regimens in HIVâ€‘1â€‘infected infants, children, and adolescents.</p>
<p>The initial dose-finding stage included intensive pharmacokinetic evaluation in 10 INSTI-naÃ¯ve subjects (aged 12 to 18 years). Dose selection was based upon achieving similar dolutegravir plasma exposure and trough concentration as seen in adults. After dose selection, an additional 13 subjects were enrolled for evaluation of long-term safety, tolerability, and efficacy.</p>
<p>These 23 subjects had a mean age of 14 years (range: 12 to 17), were 78% female and 52% black. At baseline, mean plasma HIV-1 RNA was 4.3 log<span class="Sub">10</span> copies per mL, median CD4+ cell count was 466 cells per mm3 (range: 11 to 1,025), and median CD4+% was 22% (range: 1% to 39%). Overall, 17% had baseline plasma HIV-1 RNA greater than 50,000 copies per mL and 39% had a CDC HIV clinical classification of category C. Most subjects had previously used at least 1 NNRTI (52%) or 1 PI (78%).</p>
<p>At 24 weeks, 70% of subjects treated with TIVICAY once daily (35Â mg: nÂ =Â 4, 50Â mg: nÂ =Â 19) plus OBT achieved a viral load less than 50 copies per mL. The median CD4+ cell count (percent) increase from baseline to Week 24 was 63 cells per mm3 (5%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_14c98c96-1165-4e2f-8bb3-91b7366d3c37"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">TIVICAY Tablets, 50Â mg, are yellow, round, film-coated, biconvex tablets debossed with SVÂ 572 on one side and 50 on the other side.</p>
<p>Bottle of 30 tablets with child-resistant closure	NDC 49702-228-13.</p>
<p>Store at 25<span class="Bold">Â°</span>C (77<span class="Bold">Â°</span>F); excursions permitted 15<span class="Bold">Â°</span> to 30<span class="Bold">Â°</span>C (59<span class="Bold">Â°</span> to 86<span class="Bold">Â°</span>F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_9a1e0cea-6105-4f1b-b530-ea505fbc424a"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Patient Information).</p>
<p><span class="Underline">Drug Interactions</span></p>
<p>TIVICAY should not be coadministered with dofetilide because interactions between these drugs can result in potentially life-threatening adverse events <span class="Italics">[see Contraindications (4)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>Patients should be advised to immediately contact their healthcare provider if they develop <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Instruct patients to immediately stop taking TIVICAY and other suspect agents, and seek medical attention if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with any of the following symptoms, as it may be a sign of a more serious reaction such as severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; generally ill feeling; extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>; muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>; <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of the skin; oral <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or lesions; <span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span>; <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>; <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the eyes, lips, tongue, or mouth; breathing difficulty; and/or signs and symptoms of liver problems (e.g., yellowing of the skin or whites of the eyes, dark or tea-colored urine, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-colored stools or bowel movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, loss of appetite, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, aching, or sensitivity on the right side below the ribs). Patients should understand that if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occurs, they will be closely monitored, laboratory tests will be ordered, and appropriate therapy will be initiated. Patients should also be told that it is very important that they remain under a physician's care during treatment with TIVICAY <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</p>
<p><span class="Underline">Effects on Serum Liver Biochemistries in Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></p>
<p>Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY and should be advised that they are recommended to have laboratory testing before and during therapy <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</p>
<p><span class="Underline">Fat Redistribution</span></p>
<p>Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and longâ€‘term health effects of these conditions are not known at this time <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></span></p>
<p>In some patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, signs and symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> from previous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that may have been present with no obvious symptoms. Patients should be advised to inform their healthcare provider immediately of any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</p>
<p><span class="Underline">Information about HIV</span>â€‘<span class="Underline">1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p>
<p>TIVICAY is not a cure for HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients must remain on continuous HIV therapy to control HIVâ€‘1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and decrease HIV-related illness. Inform patients that sustained decreases in plasma HIV RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Advise patients to remain under the care of a physician when using TIVICAY.</p>
<p>Advise patients to take all HIV medications exactly as prescribed. </p>
<p>Advise patients to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<p>Advise patients not to re-use or share needles or other injection equipment.</p>
<p><span class="Bold">Advise patients not to share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></p>
<p>Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</p>
<p>Female patients should be advised not to breastfeed because it is not known if TIVICAY can be passed to your baby in your breast milk and whether it could harm your baby. Mothers with HIVâ€‘1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</p>
<p>Instruct patients to read the Patient Information before starting TIVICAY and to reread it each time the prescription is renewed. Instruct patients to inform their physician or pharmacist if they develop any unusual symptom, or if any known symptom persists or worsens. </p>
<p>Instruct patients that if they miss a dose, they should take it as soon as they remember. If they do not remember until it is within 4 hours of the time for the next dose, they should be instructed to skip the missed dose and go back to the regular schedule. Patients should not double their next dose or take more than the prescribed dose.</p>
<p>TIVICAY and EPZICOM are registered trademarks of the ViiV Healthcare group of companies.</p>
<p>The other brands listed are trademarks of their respective owners and are not trademarks of the ViiV Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Â©2015, the ViiV Healthcare group of companies. All rights reserved.</p>
<p>TVC:5PI</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_91484b75-310c-4d4b-97b0-da2c12224523"></a><a name="section-16"></a><p></p>
<p class="First">Patient Information</p>
<p><span class="Bold">TIVICAY<span class="Sup">Â® </span>(TIV-eh-kay)</span></p>
<p><span class="Bold">(dolutegravir)</span></p>
<p><span class="Bold">tablets</span></p>
<p>Read this Patient Information before you start taking TIVICAY and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is TIVICAY?</span></p>
<p>TIVICAY is a prescription HIV-1 medicine that is used with other antiretroviral medicines to treat Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus-1 (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>HIV-1 is the virus that causes <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immune Deficiency Syndrome</span> (AIDS).</p>
<p>It is not known if TIVICAY is safe and effective in children under 12 years of age or who weigh less than 88 pounds.</p>
<p><span class="Bold">When used with other HIV-1 medicines to treat HIVâ€“1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, TIVICAY may help:</span></p>
<dl>
<dt>â€¢</dt>
<dd>reduce the amount of HIV-1 in your blood. This is called â€œviral loadâ€?.</dd>
<dt>â€¢</dt>
<dd>increase the number of white blood cells called CD4+ (T) cells in your blood, which help fight off other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</dd>
</dl>
<p>Reducing the amount of HIV-1 and increasing the CD4+ (T) cells in your blood may help improve your immune system. This may reduce your risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or getting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can happen when your immune system is weak (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>).</p>
<p><span class="Bold">TIVICAY does not cure HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or AIDS.</span> You must stay on continuous HIV-1 therapy to control HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and decrease HIV-related illnesses.</p>
<p><span class="Bold">Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</span></p>
<dl>
<dt>â€¢</dt>
<dd>Do not share or re-use needles or other injection equipment.</dd>
<dt>â€¢</dt>
<dd>Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</dd>
<dt>â€¢</dt>
<dd>Do not have any kind of sex without protection. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with any body fluids such as semen, vaginal secretions, or blood.</dd>
</dl>
<p>Ask your healthcare provider if you have any questions about how to prevent passing HIV to other people.</p>
<p><span class="Bold">Who should not take TIVICAY?</span></p>
<p><span class="Bold">Do not take TIVICAY if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have ever had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to a medicine that contains dolutegravir (TIVICAY, TRIUMEQ).</dd>
<dt>â€¢</dt>
<dd>take dofetilide (TIKOSYN<span class="Sup">Â®</span>). Taking TIVICAY and dofetilide (TIKOSYN) can cause side effects that may be life-threatening.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking TIVICAY?</span></p>
<p><span class="Bold">Before you take TIVICAY, tell your healthcare provider if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have ever had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to TIVICAY.</dd>
<dt>â€¢</dt>
<dd>have or had liver problems, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
<dt>â€¢</dt>
<dd>have any other medical condition.</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. It is not known if TIVICAY will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking TIVICAY.</dd>
<dt>Â </dt>
<dd>
<span class="Bold">Pregnancy Registry.</span> There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. <span class="Bold">Do not breastfeed if you take TIVICAY</span>.<dl>
<dt>â€¢</dt>
<dd>You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.</dd>
<dt>â€¢</dt>
<dd>It is not known if TIVICAY passes into your breast milk.</dd>
<dt>â€¢</dt>
<dd>Talk to your healthcare provider about the best way to feed your baby.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about the medicines you take, </span>including prescription and over-the-counter medicines, vitamins, or herbal supplements.</p>
<p>TIVICAY and other medicines may affect each other causing side effects. TIVICAY may affect the way other medicines work, and other medicines may affect how TIVICAY works.</p>
<p>Especially tell your healthcare provider if you take:</p>
<dl>
<dt>â€¢</dt>
<dd>other HIV-1 medicines including: efavirenz (SUSTIVA<span class="Sup">Â®</span>), etravirine (INTELENCE<span class="Sup">Â®</span>), fosamprenavir (LEXIVA<span class="Sup">Â®</span>)/ritonavir (NORVIR<span class="Sup">Â®</span>), nevirapine (VIRAMUNE<span class="Sup">Â®</span>), tipranavir (APTIVUS<span class="Sup">Â®</span>)/ritonavir (NORVIR).</dd>
<dt>â€¢</dt>
<dd>another medicine that contains dolutegravir (TRIUMEQ).</dd>
<dt>â€¢</dt>
<dd>antacids, laxatives or other medicines that contain aluminum, magnesium, sucralfate (CARAFATE<span class="Sup">Â®</span>), or buffered medicines. TIVICAY should be taken at least 2 hours before or 6 hours after you take these medicines.</dd>
<dt>â€¢</dt>
<dd>iron or calcium supplements. Supplements including multivitamins containing calcium or iron may be taken at the same time with TIVICAY if taken with food. Otherwise, TIVICAY should be taken at least 2 hours before or 6 hours after you take these medicines.</dd>
<dt>â€¢</dt>
<dd>anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicines:<dl>
<dt>â€¢</dt>
<dd>oxcarbazepine (TRILEPTAL<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>phenytoin (DILANTIN<span class="Sup">Â®</span>, DILANTIN<span class="Sup">Â®</span>-125, PHENYTEK<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>phenobarbital (LUMINAL<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>carbamazepine (CARBATROL<span class="Sup">Â®</span>, EQUETRO<span class="Sup">Â®</span>, TEGRETOL<span class="Sup">Â®</span>, TEGRETOL<span class="Sup">Â®</span>-XR, TERIL<span class="Sup">Â®</span>, EPITOL<span class="Sup">Â®</span>)</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>St. Johnâ€™s wort (<span class="Italics">Hypericum perforatum</span>)</dd>
<dt>â€¢</dt>
<dd>a medicine that contains metformin</dd>
<dt>â€¢</dt>
<dd>rifampin (RIFATER<span class="Sup">Â®</span>, RIFAMATE<span class="Sup">Â®</span>, RIMACTANE<span class="Sup">Â®</span>, RIFADIN<span class="Sup">Â®</span>)</dd>
</dl>
<p>Ask your healthcare provider or pharmacist if you are not sure if your medicine is one that is listed above.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take TIVICAY?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Take TIVICAY exactly as your healthcare provider tells you.</span></dd>
<dt>â€¢</dt>
<dd>Do not change your dose or stop taking TIVICAY without talking with your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>Stay under the care of a healthcare provider while taking TIVICAY.</dd>
<dt>â€¢</dt>
<dd>You can take TIVICAY with or without food.</dd>
<dt>â€¢</dt>
<dd>If you miss a dose of TIVICAY, take it as soon as you remember. If it is within 4 hours of your next dose, skip the missed dose and take the next dose at your regular time. Do not take 2 doses at the same time. If you are not sure about your dosing, call your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>Do not run out of TIVICAY. The virus in your blood may become resistant to other HIV-1 medicines if TIVICAY is stopped for even a short time. When your supply starts to run low, get more from your healthcare provider or pharmacy.</dd>
<dt>â€¢</dt>
<dd>If you take too much TIVICAY, call your healthcare provider or go to the nearest hospital emergency room right away.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of TIVICAY?</span></p>
<p><span class="Bold">TIVICAY may cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>.</span> Call your healthcare provider right away if you develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with TIVICAY. <span class="Bold">Stop taking TIVICAY and get medical help right away if you:</span>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with any of the following signs or symptoms</span><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>â€¢</dt>
<dd>generally ill feeling</dd>
<dt>â€¢</dt>
<dd>extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>â€¢</dt>
<dd>muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or sores in mouth</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of the skin</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the eyes</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the mouth, face, lips, or tongue</dd>
<dt>â€¢</dt>
<dd>problems breathing</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">develop any of the following signs or symptoms of liver problems:</span><dl>
<dt>â€¢</dt>
<dd>yellowing of the skin or whites of the eyes</dd>
<dt>â€¢</dt>
<dd>dark or tea-colored urine</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-colored stools or bowel movements</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd>loss of appetite</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, aching, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> on the right side below the ribs</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in liver tests.</span> People with a history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C virus may have an increased risk of developing new or worsening changes in certain liver tests during treatment with TIVICAY. Your healthcare provider may do tests to check your liver function before and during treatment with TIVICAY.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in body fat </span>can happen in people who take HIV-1 medicines. These changes may include increased amount of fat in the upper back and neck (â€œbuffalo humpâ€?), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The exact cause and long-term health effects of these problems are not known.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in your immune system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>)</span> can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after starting your HIV-1 medicine.</dd>
</dl>
<p><span class="Bold">The most common side effects of TIVICAY include:</span></p>
<dl>
<dt>â€¢</dt>
<dd>see â€œAllergic reactionsâ€? above</dd>
<dt>â€¢</dt>
<dd>trouble sleeping</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
</dl>
<p>Tell your healthcare provider about any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of TIVICAY. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1â€‘800â€‘FDAâ€‘1088.</p>
<p><span class="Bold">How should I store TIVICAY?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store TIVICAY at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</dd>
</dl>
<p><span class="Bold">Keep TIVICAY and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of TIVICAY.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TIVICAY for a condition for which it was not prescribed. Do not give TIVICAY to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>You can ask your pharmacist or healthcare provider for information about TIVICAY that is written for health professionals.</p>
<p>For more information, call 1-877-844-8872 or go to www.TIVICAY.com.</p>
<p><span class="Bold">What are the ingredients in TIVICAY?</span></p>
<p><span class="Bold">Active ingredient:</span> dolutegravir sodium</p>
<p><span class="Bold">Inactive ingredients:</span> d-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow, macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for:</p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Revised: August 2015</p>
<p>TVC:4PIL</p>
<p>Â©2015, the ViiV Healthcare group of companies. All rights reserved.</p>
<p>TIVICAY and LEXIVA are registered trademarks of the ViiV Healthcare group of companies.</p>
<p>The brands listed are trademarks of their respective owners and are not trademarks of the ViiV Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_44d1b4e3-a302-4c92-a769-ee2987312bbf"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 49702-228-13</span></p>
<p><span class="Bold">Tivicay<span class="Sup">Â®</span></span></p>
<p>(dolutegravir)</p>
<p>Tablets</p>
<p><span class="Bold">50 mg</span></p>
<p><span class="Bold">30 Tablets</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg of dolutegravir.</p>
<p>Store at controlled room temperature of 25Â°C (77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) (see USP).</p>
<p>See prescribing information for dosage information.</p>
<p>Manufactured for: </p>
<p>ViiV Healthcare</p>
<p>RTP, NC 27709</p>
<p>by:</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Made in Japan</p>
<p>A111024</p>
<div class="Figure">
<a name="id2383680"></a><img alt="Tivicay 50 mg 30 count label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=63df5af3-b8ac-4e76-9830-2dbb340af922&amp;name=tivicay-spl-graphic-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIVICAYÂ 		
					</strong><br><span class="contentTableReg">dolutegravir sodium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49702-228</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOLUTEGRAVIR SODIUM</strong> (DOLUTEGRAVIR) </td>
<td class="formItem">DOLUTEGRAVIR</td>
<td class="formItem">50Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SV;572;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49702-228-13</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">08/13/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204790</td>
<td class="formItem">08/13/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>ViiV Healthcare Company
							(027295585)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2fa9bc7c-2392-4265-9d04-57a9f66c4176</div>
<div>Set id: 63df5af3-b8ac-4e76-9830-2dbb340af922</div>
<div>Version: 7</div>
<div>Effective Time: 20150806</div>
</div>
</div>Â <div class="DistributorName">ViiV Healthcare Company</div></p>
</body></html>
